Close Menu

Adaptive Biotechnologies

An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.

The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.

The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.

The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.

The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.